Nippon Chemiphar : Business Summary FY2023.

FY2023 Business Summary

(Year Ended March 31, 2024)

（TSE 4539）

I. FY2023 Business Results

1

Sales and Income to Year-on-Year

(¥mn)

			FY2022		FY2023
				% of
			Amount	Sales
Net sales	31,559	100.0
	Pharmaceutical products segment	30,543	96.8
		Generics, proprietary products
		and new drugs	26,148	82.9
		Diagnostics	2,780	8.8
	Others segment	1,015	3.2
Cost of sales	23,374	74.1
SG&A expenses	8,425	26.7
	R&D expenses	2,419	7.7
Operating profit/loss	(241)	－
Ordinary profit/1oss	58	0.2
Net profit attributable to
owners of parent/loss	339	1.1

2

Sales and Income to Full Year Forecasts

(¥mn)

					FY2022
						% of
					Amount	Sales
	Net sales	31,559	100.0
		Pharmaceutical products segment	30,543	96.8
			Generics, proprietary products
			and new drugs	26,148	82.9
			Diagnostics	2,780	8.8
		Others segment	1,015	3.2
	Cost of sales	23,374	74.1
	SG&A expenses	8,425	26.7
		R&D expenses	2,419	7.7
	Operating profit/loss	(241)	－
	Ordinary profit/loss	58	0.2
	Net profit attributable to
	owners of parent/loss	339	1.1

FY2023

1. Issued on May 7, 2024.
2. Issued on May 12, 2023.

3

Pharmaceutical Sales to Year-on-Year

Generics, Proprietary Products and New Drugs		(¥mn)
			FY2022		FY2023
				% of
			Amount	Sales
Total	26,148	100.0
	Generics	24,803	94.9
		To medical institutions	23,698	－
		To other makers*	1,105	－
	Proprietary products and new drugs	1,345	5.1
		Uralyt	575	－
		Others	769	－
Chemiphar, ODM Generics
Total	25,881	－
	Generics (ODM)	1,078	－

* Includes exports.

4

Pharmaceutical Sales to Full Year Forecasts

Generics, Proprietary Products and New Drugs		(¥mn)
			FY2022		FY2023
				% of
			Amount	Sales
Total	26,148	100.0
	Generics	24,803	94.9
		To medical institutions	23,698	－
		To other makers*	1,105	－
	Proprietary products and new drugs	1,345	5.1
		Uralyt	575	－
		Others	769	－
Chemiphar, ODM Generics
Total	25,881	－
	Generics (ODM)	1,078	－

* Includes exports.

5

Sales Distribution by Launch Year

					(¥mn)
	FY2022		FY2023
		Distrib.		Product Lineup
	Amount	(%)
FY2019 and before	22,607		91.1
FY2020	1,278		5.2		・Memantine
		・Celecoxib
FY2021	414		1.7		・Eszopiclone
		・Duloxetine
FY2022	502		2.0		・Febuxostat
		・Esomeprazole
FY2023	－	－		・Azilsartan
Total	24,803		100.0

6

Balance Sheet

							(¥mn)
	FY2022			FY2023
	March 31,2023				Reason for changes
							Acquisition of shares and
				Cash and deposits	(1,329)	payment for construction.
				Notes and accounts
				receivable―trade, and	272
				contract assets
Current assets	33,436			Inventories	(32)
				Construction in
				progress	2,242	*
Non-current assets	15,134			Investment securities			Third-party share allocation
		681	by Delta-Fly Pharma, Inc.
Total assets	48,571
				Purchase payables	(1,965)	YOY decrease in purchases.
Current liabilities	14,766			Current portion of long-term
		borrowings	150
Non-current liabilities	15,270			Long-term borrowings	1,393	*
Total net assets	18,534
Total liabilities and net assets	48,571

* Additional installation at Building No. 3 of our Tsukuba Factory.

7

Cash Flow

(¥mn)	(¥mn)

8

Expenditure and Per Share Information

Expenditure					(¥mn)
	FY2022		FY2023
			YOY		Usage
	Amount	Amount	(%)	Forecast	Rate (%)
Capital expenditure	573	2,747	378.9	3,700	74.3
Depreciation and amortization	1,500	1,459	(2.7)	1,450	100.7

Note to increase in capital expenditure:

We expended for additional installation at Building No. 3 of our Tsukuba Factory to meet the need for increased production.

Per Share Information				(¥)
	FY2022		FY2023
	Amount	Amount	Change	Forecast
Earnings per share	94.07	(50.14)	(144.21)	16.62
Book value per share	5,130.65	5,116.02	(14.63)	－
Dividends per share	50.00	50.00	－	50.00
Dividend payout ratio (%)	53.2	－	－	300.8

9